Role of RAI* after Thyroidectomy in Primary Management of Differentiated Thyroid Cancer (1)
| Recommendation no. | ATA guidance |
| 51A | Radioactive iodine remnant ablation is not routinely recommended after thyroidectomy for ATA low risk differentiated thyroid cancer patients. Consideration of specific features of the individual patient that could modulate recurrence risk, disease follow-up implications, and patient preferences are relevant to radioactive iodine decision-making. (Weak recommendation, Low quality evidence) |
| 51B | Radioactive iodine remnant ablation is not routinely recommended after lobectomy or total thyroidectomy for patients with unifocal papillary microcarcinoma, in the absence of other adverse features. (Strong recommendation, Moderate quality evidence) |
| 51C | Radioactive iodine remnant ablation is not routinely recommended after thyroidectomy for patients with multifocal papillary microcarcinoma in the absence of other adverse features. Consideration of specific features of the individual patient that could modulate recurrence risk, disease follow-up implications, and patient preferences are relevant to radioactive iodine decision-making. (Weak recommendation, Low quality evidence) |
| 51D | Radioactive iodine adjuvant therapy should be considered after total thyroidectomy in ATA intermediate risk level differentiated thyroid cancer patients. (Weak recommendation, Low quality evidence) |
| 51E | Radioactive iodine adjuvant therapy is routinely recommended after total thyroidectomy for ATA high risk differentiated thyroid cancer patients. (Strong recommendation, Moderate quality evidence) |
↵* Including remnant ablation, adjuvant therapy, or therapy for persistent disease.